Literature DB >> 29796696

[Effect of performing a single PSA screening : The CAP trial].

R Al-Monajjed1, C Arsov2, P Albers2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29796696     DOI： 10.1007/s00120-018-0678-3

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  6 in total

1.  Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.

Authors:  Christian Arsov; Nikolaus Becker; Boris A Hadaschik; Markus Hohenfellner; Kathleen Herkommer; Jürgen E Gschwend; Florian Imkamp; Markus A Kuczyk; Gerald Antoch; Glen Kristiansen; Roswitha Siener; Axel Semjonow; Freddie C Hamdy; Hans Lilja; Andrew J Vickers; Fritz H Schröder; Peter Albers
Journal:  Eur Urol       Date:  2013-05-14       Impact factor: 20.096

2.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Authors:  Hans Lilja; David Ulmert; Thomas Björk; Charlotte Becker; Angel M Serio; Jan-Ake Nilsson; Per-Anders Abrahamsson; Andrew J Vickers; Göran Berglund
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

3.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

4.  Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Authors:  Sigrid V Carlsson; Tiago M de Carvalho; Monique J Roobol; Jonas Hugosson; Anssi Auvinen; Maciej Kwiatkowski; Arnauld Villers; Marco Zappa; Vera Nelen; Alvaro Páez; James A Eastham; Hans Lilja; Harry J de Koning; Andrew J Vickers; Eveline A M Heijnsdijk
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860

5.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

6.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Authors:  Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja
Journal:  BMJ       Date:  2013-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.